Phase III clinical trial - Sein métastatique triple négatif

EPIK-B3 (CBYL719H12301)
Sein métastatique triple négatif
Essai clinique fermé
Public cible
Adulte
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Description de l'essai
The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss without PIK3CA mutation (Study Parts B1 and B2)
Liens utiles
Lien de l'essai
Vignette
FLORENCE COUSSY
Investigateur principal
Vignette
FLORENCE COUSSY
Investigateur principal